No connection

Search Results

ADMA vs KNSA

ADMA
ADMA Biologics, Inc.
BEARISH
Price
$15.15
Market Cap
$3.61B
Sector
Healthcare
AI Confidence
85%
KNSA
Kiniksa Pharmaceuticals International, plc
NEUTRAL
Price
$47.08
Market Cap
$3.6B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ADMA
25.25
KNSA
62.77
Forward P/E
ADMA
10.98
KNSA
29.03
P/B Ratio
ADMA
7.55
KNSA
6.33
P/S Ratio
ADMA
7.07
KNSA
5.32
EV/EBITDA
ADMA
18.04
KNSA
40.61

Profitability

Gross Margin
ADMA
57.38%
KNSA
54.66%
Operating Margin
ADMA
45.09%
KNSA
9.78%
Profit Margin
ADMA
28.8%
KNSA
8.71%
ROE
ADMA
35.56%
KNSA
11.73%
ROA
ADMA
21.5%
KNSA
7.18%

Growth

Revenue Growth
ADMA
18.4%
KNSA
65.0%
Earnings Growth
ADMA
-52.8%
KNSA
--

Financial Health

Debt/Equity
ADMA
0.17
KNSA
0.02
Current Ratio
ADMA
6.71
KNSA
3.79
Quick Ratio
ADMA
3.54
KNSA
3.09

Dividends

Dividend Yield
ADMA
--
KNSA
--
Payout Ratio
ADMA
0.0%
KNSA
0.0%

AI Verdict

ADMA BEARISH

ADMA's Piotroski F-Score of 3/9 indicates weak financial health, signaling distress risk despite strong profitability metrics. The company trades at a high P/E of 25.25 and Price/Sales of 7.07, significantly above sector averages, suggesting overvaluation. While gross and operating margins are impressive (57.38% and 45.09%), earnings have collapsed YoY by 52.8%, undermining growth credibility. Insider selling totaling $1.58M in the last six months, including multiple large sales by the CEO, reinforces bearish sentiment. The Graham Number of $5.21 and intrinsic value of $4.2 suggest deep undervaluation, but the current price of $15.15 reflects a premium driven by speculative growth expectations rather than fundamentals.

Strengths
Exceptional gross and operating margins (57.38% and 45.09%) indicate strong pricing power and cost control
High ROE of 35.56% demonstrates efficient use of equity capital
Low debt/equity ratio of 0.17 and high current ratio of 6.71 signal strong financial stability
Risks
Piotroski F-Score of 3/9 indicates weak financial health and high distress risk
Earnings have declined sharply by 52.8% YoY, contradicting revenue growth of 18.4%
Insider selling of $1.58M in six months, including multiple large sales by the CEO, signals lack of confidence
KNSA NEUTRAL

KNSA exhibits strong deterministic health with a Piotroski F-Score of 7/9 and a pristine balance sheet (Debt/Equity 0.02), yet it faces a severe valuation disconnect. The current price of $47.08 trades at a massive premium to its Graham Number ($11.20) and Intrinsic Value ($5.25), suggesting the market is pricing in aggressive future growth. While revenue growth is impressive at 65% YoY, the company has missed earnings estimates in 4 consecutive quarters with an average surprise of -35.29%. This fundamental instability, coupled with heavy C-suite insider selling and a bearish technical trend, offsets the strong financial health.

Strengths
Strong Piotroski F-Score (7/9) indicating robust financial health
Exceptional liquidity with a Current Ratio of 3.79 and Quick Ratio of 3.09
Negligible leverage with a Debt/Equity ratio of 0.02
Risks
Extreme valuation premium relative to Graham and Intrinsic value baselines
Consistent failure to meet earnings expectations (0/4 beats in last 4 quarters)
Bearish insider sentiment with significant selling by CEO, CFO, and COO

Compare Another Pair

ADMA vs KNSA: Head-to-Head Comparison

This page compares ADMA Biologics, Inc. (ADMA) and Kiniksa Pharmaceuticals International, plc (KNSA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile